Please ensure Javascript is enabled for purposes of website accessibility

An Apple Scare

By Alyce Lomax – Updated Nov 16, 2016 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Steve Jobs' cancer scare is an understandable concern, but no reason for panic.

There's quite a buzz among investors and technology fanatics today after Apple Computer's (NASDAQ:AAPL) fearless leader, Steve Jobs, revealed that he had surgery for pancreatic cancer over the weekend. It brought worries about the company's succession plan to the forefront of investors' minds and, indeed, thoughts of what Apple would be without its core -- Jobs.

Granted, it's an inopportune time for a scare like this. Apple's on the tip of many tongues these days; Jobs' face has been plastered on magazine covers at your local supermarket based on the success of the iPod, and whether Apple will dominate music has moved to conversation topic lists at happy hours, parties, and barbecues. Apple's third-quarter earnings sang on the company's musical strength.

Jobs, who is also CEO of Pixar (NASDAQ:PIXR), said that the form of pancreatic cancer he had is a relatively benign one, and if caught in time, is cured. (Fortunately, he discovered it early, he said in a companywide email sent using his PowerBook and an Airport Express, according to an email transcript provided by Associated Press.) He said he will take August off and that Vice President Timothy Cook will lead the company in his absence.

Apple shares sank nearly 4% in early morning trading, although recently investors calmed down a bit, with the stock down about 2%. Indeed, Jobs is about as synonymous with his company as Warren Buffett is for Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) or Bill Gates is for Microsoft (NASDAQ:MSFT). Granted, investors are likely also spooked, given the memory of the abrupt death of McDonalds' (NYSE:MCD) Jim Cantalupo in April. Some negative sentiment regarding a cancer scare in a company's high-profile leader is understandable.

However, it seems unfortunate that anyone would bid down the shares in a knee-jerk reaction to news like this, where most of the panic relates to conjecture. And many would argue that there are other, far better reasons to scrutinize an Apple investment, including concerns about lofty share valuation and steadily increasing competition.

What do you think? Do you wish Apple would discuss a succession plan? How badly would the company flounder without Jobs' leadership? Fools are talking about today's news about Jobs on the Apple discussion board.

Alyce Lomax does not own shares of any of the companies mentioned.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

McDonald's Corporation Stock Quote
McDonald's Corporation
MCD
$245.95 (-0.80%) $-1.99
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$237.92 (-1.27%) $-3.06
Apple Inc. Stock Quote
Apple Inc.
AAPL
$150.43 (-1.51%) $-2.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.